<DOC>
	<DOCNO>NCT00310167</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill cancer cell . It yet know regimen low-dose radiation therapy effective treat follicular non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two different regimen low-dose radiation therapy ( 24Gy versus 4Gy ) compare well work treat patient follicular marginal zone non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Low-Dose Radiation Therapy Treating Patients With Follicular Marginal Zone Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare local progression-free interval patient follicular non-Hodgkin 's lymphoma ( NHL ) treat 2 different regimen low-dose radiotherapy . Secondary - Compare acute toxicity 4 week patient treat regimen . - Compare late toxicity patient treat regimen . - Compare tumor response 12 week patient treat regimen . - Compare overall survival patient treat regimen . - Assess health economics regimens patient . OUTLINE : This multicenter , randomize study . Patients randomize one two treatment arm . - Arm I 4Gy : Patients undergo low-dose radiotherapy daily day 1 2 . - Arm II 24Gy : Patients undergo low-dose radiotherapy daily day 1-5 , 8-12 , 15 , 16 . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study therapy , patient follow 5 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 650 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular mmarginal zone nonHodgkin 's lymphoma ( NHL ) Any stage Radiotherapy indicate curative treatment stage IA IIA disease OR palliation due tumor bulk anatomical position PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>Marginal zone lymphoma</keyword>
</DOC>